Debt to Equity Ratio Chart

View Debt to Equity Ratio for AMGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 4.903
March 31, 2026 6.238
December 31, 2025 6.403
September 30, 2025 5.675
June 30, 2025 7.566
March 31, 2025 9.245
December 31, 2024 10.36
September 30, 2024 8.024
June 30, 2024 10.57
March 31, 2024 12.75
December 31, 2023 10.50
September 30, 2023 7.898
June 30, 2023 9.076
March 31, 2023 11.52
December 31, 2022 10.83
September 30, 2022 10.60
June 30, 2022 15.10
March 31, 2022 40.23
December 31, 2021 5.072
September 30, 2021 4.573
June 30, 2021 3.975
March 31, 2021 3.502
December 31, 2020 3.555
September 30, 2020 3.129
June 30, 2020 3.211
Date Value
March 31, 2020 3.358
December 31, 2019 3.146
September 30, 2019 2.771
June 30, 2019 2.882
March 31, 2019 3.094
December 31, 2018 2.714
September 30, 2018 2.399
June 30, 2018 2.314
March 31, 2018 2.275
December 31, 2017 1.400
September 30, 2017 1.110
June 30, 2017 1.105
March 31, 2017 1.113
December 31, 2016 1.158
September 30, 2016 1.148
June 30, 2016 1.102
March 31, 2016 1.196
December 31, 2015 1.124
September 30, 2015 1.136
June 30, 2015 1.163
March 31, 2015 1.145
December 31, 2014 1.192
September 30, 2014 1.302
June 30, 2014 1.367
March 31, 2014 1.408

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Gilead Sciences, Inc. 2.219
Regeneron Pharmaceuticals, Inc. 0.0854
AbbVie, Inc. -11.93
Biogen, Inc. 0.4433
Vertex Pharmaceuticals, Inc. 0.0977